EASE OF MOVEMENT
Trading: BUY @ $196.19
Signal Strength: MEDIUM
Volatility indicators highlight potential moves of a stock which can either move sharply in the updwards or downwards direction. This indicator allows stocks to be compared on a level playing field to highlight high and low volatility. Normally, falling markets are more likely to be volatile than a rising markets due to the emotion that gets tied to trading. Use volatility indicators in conjunction with other indicators to reduce exposure to false moves.
CSL (ASX:CSL) current price have moved upwards on low volume. Currently, the EOM is 356.985.
The Ease of Movement (EOM) is a technical momentum indicator that is used to illustrate the relationship between the rate of an assets price change and its volume. This indicator attempts to identify the amount of volume required to move prices. Generally a value greater than zero is an indication that the stock is being accumulated (bought) and negative values are used to signal increased selling pressure. A high positive value appears when prices move upward on low volume. Strong negative numbers indicate that price is moving downward on low volume.
Calculation: Ease of Movement (EOM):
1) Distance Moved = ((H + L)/2 - (Prior H + Prior L)/2);
2) Box Ratio = ((V/100 000 000)/(H - L));
3) 1-Period EMV = ((H + L)/2 - (Prior H + Prior L)/2) / ((V/100 000 000)/(H - L));
4) 14-Period Ease of Movement = 14-Period simple moving average of 1-period EMV
PROFILE: CSL (CSL.AX)
Stock Exchange: ASX
Ticker Codes: | CSL.AX | ASX:CSL |
CSL Limited engages in the research, development, manufacture, marketing, and distribution of biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, and internationally. It operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of bleeding disorders, including hemophilia and von Willebrand disease, primary and secondary immunodeficiency's, hereditary angioedema, neurological disorders, and inherited respiratory diseases. Its products are also used to prevent haemolytic diseases in newborns and infections in solid organ transplant recipients, as well as specific infections; and for urgent warfarin reversal in patients with acute major bleeding, as well as victims of trauma, shocks, and burns. In addition, this segment operates approximately 180 human blood plasma collection centers. Further, it conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and offers influenza vaccines. It also provides in-licensed vaccines and specialty pharmaceuticals; manufactures and markets diagnostics for immunohematology laboratories; and supplies a range of products, including antivenoms and Q fever vaccines. The company was founded in 1916 and is headquartered in Parkville, Australia.
Ease of MovementDownload
|AJM Altura Mining||0.17||6.5||2,423,817||0||BULLISH|
|SFR Sandfire Resources||7.06||6||1,338,899||0.09||BULLISH|
|KDR Kidman Resources||1.23||5.2||2,238,007||10.96||BULLISH|
|FIG Freedom Insurance||0.02||4.8||45,729||32.2||BULLISH|
|TWE Treasury Wine Estates||15.34||4.1||2,057,913||1.99||BULLISH|